
CVSA Stock Forecast & Price Target
CVSA Analyst Ratings
Bulls say
Covista is projected to have increased revenue and earnings, led by their successful Chamberlain/Walden segments and a strong EBITDA performance from their CVSA division. There are some potential risks, but their focus on clinical healthcare, partnerships, and expansion plans make them well-positioned for future growth. Despite being undervalued, the company has a strong executive team and a new growth strategy, making it an "OUTPERFORM" investment with a target price of $170.
Bears say
Covista is a for-profit healthcare education company facing challenges with declining enrollments in its nursing segment, Chamberlain, and potential liabilities from its former subsidiary, DeVry University. While there may be some signs of improvement, there are risks to the company's outlook, including increased competition and the possibility of regulatory changes. Additionally, the stock has underperformed due to concerns about the Chamberlain segment, and there is uncertainty around the success of its turnaround plan. Financially, the company has shown strong recent performance, with guidance for continued growth, but there are downside risks to consider. Overall, the company's outlook is negative, with potential for continued underperformance and challenges for its business model.
This aggregate rating is based on analysts' research of Adtalem Global Education Inc and is not a guaranteed prediction by Public.com or investment advice.
CVSA Analyst Forecast & Price Prediction
Start investing in CVSA
Order type
Buy in
Order amount
Est. shares
0 shares